SINGLE CENTRE SURVIVAL OUTCOMES IN THE TREATMENT OF INTERMEDIATE AND HIGH-RISK MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKAEMIA WITH 5-AZACITIDINE

被引：0
|
作者：
Stringer, R. [1 ]
Rider, D. T. [2 ]
Newman, D. J. [2 ]
Grace, D. R. [2 ]
机构：
[1] Brighton & Sussex Med Sch, Brighton, E Sussex, England
[2] East Sussex Healthcare NHS Trust, Eastbourne, England
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1835
引用
收藏
页码：725 / 726
页数：2
相关论文
共 50 条
  • [21] Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome
    Yanada, Masamitsu
    Huang, Xuelin
    Garcia-Manero, Guillermo
    O'Brien, Susan
    Ravandi, Farhad
    Borthakur, Gautam
    Faderl, Stefan
    Issa, Jean-Pierre
    Kantarjian, Hagop
    Estey, Elihu
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (04) : 555 - 557
  • [22] Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome
    Raffoux, Emmanuel
    Cras, Audrey
    Recher, Christian
    Boelle, Pierre-Yves
    de Labarthe, Adrienne
    Turlure, Pascal
    Marolleau, Jean-Pierre
    Reman, Oumedaly
    Gardin, Claude
    Victor, Maud
    Maury, Sebastien
    Rousselot, Philippe
    Malfuson, Jean-Valere
    Maarek, Odile
    Daniel, Marie-Therese
    Fenaux, Pierre
    Degos, Laurent
    Chomienne, Christine
    Chevret, Sylvie
    Dombret, Herve
    ONCOTARGET, 2010, 1 (01) : 34 - 42
  • [23] Early discontinuation of empirical antibiotic treatment in neutropenic patients with acute myeloid leukaemia and high-risk myelodysplastic syndrome
    Niessen, F. A.
    van Mourik, M. S. M.
    Bruns, A. H. W.
    Raijmakers, R. A. P.
    de Groot, M. C. H.
    van der Bruggen, T.
    ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL, 2020, 9 (01)
  • [24] Early discontinuation of empirical antibiotic treatment in neutropenic patients with acute myeloid leukaemia and high-risk myelodysplastic syndrome
    F. A. Niessen
    M. S. M. van Mourik
    A. H. W. Bruns
    R. A. P. Raijmakers
    M. C. H. de Groot
    T. van der Bruggen
    Antimicrobial Resistance & Infection Control, 9
  • [25] Azacitidine therapy in high-risk myelodysplastic syndromes (MDS): A single centre experience
    Improta, S.
    Gagliardi, A.
    Villa, M. R.
    Della Cioppa, P.
    Esposito, M.
    Izzo, G. Nitrato
    Mastrullo, L.
    LEUKEMIA RESEARCH, 2013, 37 : S152 - S152
  • [26] Conditioning regimens for HSCT for patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukaemia
    Zhang, Xi
    LANCET HAEMATOLOGY, 2023, 10 (03): : e159 - e160
  • [27] Outcome of 5-Azacitidine and Decitabine Treatment in Elderly Patients with Myelodysplastic Syndrome
    Nam, Seung-Hyun
    Lim, Taekyu
    Kim, Bong-Seog
    BLOOD, 2012, 120 (21)
  • [28] OUTCOME OF 5-AZACITIDINE AND DECITABINE TREATMENT IN ELDERLY PATIENTS WITH MYELODYSPLASTIC SYNDROME
    Nam, S.
    Lim, T.
    Kim, B.
    HAEMATOLOGICA, 2013, 98 : 588 - 588
  • [29] Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study
    DiNardo, Courtney D.
    Daver, Naval
    Jabbour, Elias
    Kadia, Tapan
    Borthakur, Gautam
    Konopleva, Marina
    Pemmaraju, Naveen
    Yang, Hui
    Pierce, Sherry
    Wierda, William
    Bueso-Ramos, Carlos
    Patel, Keyur P.
    Cortes, Jorge E.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    LANCET HAEMATOLOGY, 2015, 2 (01): : E12 - E20
  • [30] INFECTIOUS COMPLICATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKEMIA TREATED WITH 5-AZACITIDINE
    Ramos, S.
    Santos, M.
    Tenreiro, R.
    Pereira, M.
    Cortesao, E.
    Rito, L.
    Ribeiro, M. L.
    HAEMATOLOGICA, 2015, 100 : 474 - 475
12345